(281)-719-8904 KenFaulkenberry@AAAMP.com

Amgen (AMGN) Dividend Stock Analysis

by

Biotechnology Research
Amgen Logo
Cell Membrane

Amgen Dividend

(updated 2/23/2018)

The Amgen (AMGN) dividend has been paid continuously since 2011 and increased for 7 consecutive years; qualifying the company as a Dividend Challenger.

Price: $186.71
Dividend Yield: 2.8%

Current Dividend: $5.28
Cash Flow From Operations (CFO) Per Share (ttm): $15.22
Free Cash Flow Per Share (ttm): $14.31

Market Capitalization: 135 B
Enterprise Value: 125 B

Dividend Analyzer Checklist

(updated January 2018)

Dividend Safety Score (27/33 points)

Dividend Payout Ratio (ttm): 40%
Cash Dividend Payout Ratio (ttm): 31% (11/12 points)
Net Financial Debt: $-5575 M
Total Assets: $80331 M
Net Financial Debt / Total Assets: – 7% (11/12 points)
Net Financial Debt to EBITDA (ttm): 282%
Piotroski Score (1-9) (TTM): (5/9 points)

Profitability Score (15/33 points)

Operating Earnings Yield (ttm): 7.7% (8/15 points)
Net Income (ttm): $8178 M
Gross Profit (ttm): $18395 M
Total Assets: $80331 M
Gross Profitability Ratio = Gross Profit / Total Assets: 24% (7/18 points)
Cash Return On Invested Capital (CROIC)(tttm): 16%
Return on Invested Capital (ROIC): 12%

Valuation Score (24/34 points)

Free Cash Flow Yield (ttm): 7.9% (15/17 points)
EV to EBIT (ttm): 11.8
EV to EBITDA (ttm): 10.0 (9/17 points)
Price to Sales Ratio (ttm): 5.7
Price to Book Value (ttm): 4.0
Price to Earnings Ratio (P/E) (ttm): 16
PE 10: 29

TOTAL POINTS – (66/100) (50 is an average score)

Latest Earnings Report: 10/25/17
Next Earning Report: 2/02/18

Stay Updated All the Time!

DVB Analyzer Bundle: Dividend Analyzer Newsletter & Dividend Sortable Excel Spreadsheet

DVB Portfolio Bundle: Dividend Portfolio & Treasure Trove Twelve Newsletters

SPECIAL 4 For 1 Price: DVB Full Membership

Learn More

Rankings & Recommendations

(updated January 2018 )

Amgen (AMGN) is ranked #43 (out of 371) overall and #5 (out of 31) in the Healthcare sector by the Dividend Analyzer.

 

Type of Investor / Recommendation
Large Diversified Dividend Portfolios / Should Be Considered
Looking For Exposure to the Healthcare Sector / Should Be Considered
Deep Value Investors / Can Be Considered

Position Disclosures:
DVB Portfolio – None
AAAMP Global Value Portfolio – None
AAAMP Retirement Growth & Income Portfolio – Long
AAAMP Treasure Trove Twelve Portfolio – Long

Company Description

Sector: Healthcare
Industry: Biotechnology

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases.

Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen’s acquisition of Onyx bolsters the firm’s therapeutic oncology portfolio with Nexavar and Kyprolis.

Discover, Compare, and Evaluate Dividend Stocks

DVB Analyzer Bundle: Dividend Analyzer Newsletter & Dividend Sortable Excel Spreadsheet - $68/year

DVB Portfolio Bundle: Dividend Portfolio & Treasure Trove Twelve Newsletters - $68/year

SPECIAL 4 For 1 Price: DVB Full Membership: Both Bundles for $99/year

Learn More
Disclaimer: While Arbor Investment Planner has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability, or completeness of third-party information presented herein. The sole purpose of this analysis is information. Nothing presented herein is, or is intended to constitute investment advice. Consult your financial advisor before making investment decisions.
Share This